H.C. Wainwright raised the firm’s price target on Zymeworks (ZYME) to $13 from $12 and keeps a Neutral rating on the shares following the Q4 report. The firm believes the company’s balance sheet should be sufficient to fund operations into the second half of 2027.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks price target raised to $19 from $18 at Citi
- Zymeworks: Promising Pipeline and Financial Stability Justify Buy Rating
- Zymeworks Faces Challenges in Diagnostic Test Development Amidst Regulatory Changes
- Zymeworks’ Earnings Call: Achievements and Challenges
- Zymeworks: Hold Rating Amid Limited Near-Term Catalysts and Strategic Resource Allocation